首页> 美国卫生研究院文献>Lippincott Williams Wilkins Open Access >PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

【2h】

PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

机译：代名词：晚期非鳞状非小细胞肺癌患者一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗+贝伐珠单抗一线治疗的随机开放标签III期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction:PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC).

机译：简介：PRONOUNCE比较了培美曲塞+卡铂，培美曲塞（Pem + Cb）与紫杉醇+卡铂+贝伐单抗+贝伐单抗（Pac + Cb + Bev）在晚期非鳞状非小细胞肺癌（NSCLC）中的疗效和安全性）。

著录项

期刊名称 Lippincott Williams Wilkins Open Access
作者
Ralph G. Zinner; Coleman K. Obasaju; David R. Spigel; Robert W. Weaver; J. Thaddeus Beck; David M. Waterhouse; Manuel R. Modiano; Borys Hrinczenko; Petros G. Nikolinakos; Jingyi Liu; Andrew G. Koustenis; Katherine B. Winfree; Symantha A. Melemed; Susan C. Guba; Waldo I. Ortuzar; Durisala Desaiah; Joseph A. Treat; Ramaswamy Govindan; Helen J. Ross;
展开▼
作者单位

展开▼
年(卷),期 -1(10),1
年度 -1
页码 134–142
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
Advanced nonsquamous non-small-cell lung cancer Efficacy Safety Combination therapy Pemetrexed Carboplatin Paclitaxel Bevacizumab;

机译：晚期非鳞状非小细胞肺癌;疗效;安全性;联合治疗;培美曲塞;卡铂;紫杉醇;贝伐单抗;
入库时间 2022-08-21 11:00:20

相似文献

外文文献
中文文献

1. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Zinner Ralph G., Obasaju Coleman K., Spigel David R., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第1期

机译：释放：随机，开放标签，第一线Pemetrexed Plus Carboplatin的第三阶段研究，然后进行维持培养型Pemetrexed与PACLitaxel Plus Carboplatin Plus Bevacizumab，然后在患者中进行维护贝伐单抗，患者患者先进的非小细胞肺癌
2. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Zinner Ralph G., Obasaju Coleman K., Spigel David R., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第1期

机译：方案：对于晚期非鳞状非小细胞肺癌患者，一线培美曲塞加卡铂联合维持培美曲塞与紫杉醇加卡铂+贝伐单抗联合贝伐珠单抗治疗的一线随机，开放标签III期研究
3. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. [J] . Patel JD, Bonomi P, Socinski MA, Clinical lung cancer . 2009,第4期

机译：突破性研究的治疗原理和研究设计：培美曲塞/卡铂/贝伐单抗的随机，开放标签III期研究，然后进行培美曲塞/贝伐单抗与紫杉醇/卡铂/贝伐单抗的维持治疗，对IIIB或IV期非鳞状非IV期患者进行贝伐珠单抗治疗-小细胞肺癌。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer [O] . Jyoti D. Patel, Mark A. Socinski, Edward B. Garon, -1

机译：PointBreak：培美曲塞加卡铂和贝伐单抗继之维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐珠单抗继之贝伐单抗维持治疗
6. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer [O] . Zinner Ralph G., Obasaju Coleman K., Spigel David R., 2015

机译：方案：对于晚期非鳞状非小细胞肺癌患者，一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗联合贝伐珠单抗治疗的一线随机，开放标签，III期研究

PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

摘要

著录项

相似文献

相关主题

期刊订阅